DaeWoong Pharmaceutical Announces Continuation of Global Phase 2 Clinical Trial for Bersiporocin
DaeWoong Pharmaceutical Co., Ltd. announced that its idiopathic pulmonary fibrosis (IPF) drug candidate, Bersiporocin (DWN12088), will continue its global Phase 2 clinical trial following a positive safety review by the Independent Data Monitoring Committee (IDMC).
The IDMC conducted an in-depth evaluation of interim safety data from 89 enrolled patients and found no significant safety concerns. To date, 94 participants have been enrolled, representing approximately 92% of the target population of 102 patients.
The third Independent Data Monitoring Committee review confirms safety and continuation of the study.
- 94 patients enrolled out of 102 planned across Korea and the U.S.
- The study is progressing as planned.
Author's summary: DaeWoong Pharmaceutical continues Phase 2 trial for Bersiporocin.